The Bombay High Court has ordered the removal of Shreya Life Sciences’ antibiotic trademark Lefoxin Biox from the register, ruling that it was too similar to Glaxo Group’s long-established heart drug Lanoxin. The court gave Shreya until December 31 to rebrand and communicate the change, with the new name to take effect from January 1, 2027.